Source:http://linkedlifedata.com/resource/pubmed/id/17593027
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-6-26
|
| pubmed:abstractText |
Membrane-bound and soluble human leucocyte antigen-G (sHLA-G) molecules display immunotolerant properties favouring tumour cell escape from immune surveillance. sHLA-G molecules have been detected in several tumour pathologies; this study aimed to evaluate sHLA-G expression in lymphoproliferative disorders. sHLA-G plasma level was significantly increased in 110 of 178 newly diagnosed lymphoid proliferations cases i.e. 59% of chronic lymphocytic leukaemia, 65% of B non-Hodgkin lymphomas (NHL) and 58% of T-NHL. To assess the mechanisms involved in this secretion, the differential effect of cytokines was tested in in vitro cultures of NHL cells. A significant induction of sHLA-G level was shown in T-NHL in contrast with B-NHL and normal equivalent cells, after cytokine stimulation with (i) interferongamma (IFNgamma), interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor, (ii) IL-10 and (iii) transforming growth factor beta. An impact of microenvironment on sHLA-G expression was found in B-NHL as shown by the in vitro effect of addition of normal monocytes. Finally, a functional effect of sHLA-G molecules purified from pathologic plasma was demonstrated by their strong capacity to inhibit T-cell proliferation at concentrations currently observed during these disorders. These results suggest that functional sHLA-G molecules are upregulated in lymphoproliferative disorders which can support their potential immunomodulatory role during this pathology.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-G Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0007-1048
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
138
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
202-12
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:17593027-B-Lymphocytes,
pubmed-meshheading:17593027-Cell Division,
pubmed-meshheading:17593027-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:17593027-HLA Antigens,
pubmed-meshheading:17593027-HLA-G Antigens,
pubmed-meshheading:17593027-Histocompatibility Antigens Class I,
pubmed-meshheading:17593027-Humans,
pubmed-meshheading:17593027-Interferon-gamma,
pubmed-meshheading:17593027-Interleukins,
pubmed-meshheading:17593027-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17593027-Lymphoma, B-Cell,
pubmed-meshheading:17593027-Lymphoma, T-Cell,
pubmed-meshheading:17593027-Lymphoproliferative Disorders,
pubmed-meshheading:17593027-Monocytes,
pubmed-meshheading:17593027-Prospective Studies,
pubmed-meshheading:17593027-T-Lymphocytes,
pubmed-meshheading:17593027-Transforming Growth Factor beta,
pubmed-meshheading:17593027-Tumor Cells, Cultured
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders.
|
| pubmed:affiliation |
UPRES Immunologie Hématologie, Université de Rennes 1, Rennes, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|